Alzheimer´s drugs rejected for NHS because benefits... ○
found
a story from The Daily Mail 💩 › The Daily Mail
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
The National Institute for Health and Care Excellence is standing by its earlier decision to turn down donanemab and lecanemab after considering new information.